Abstract

Objective To evaluate the efficacy of stereotactic body radiation therapy (SBRT) on the survival of patients with early stage pancreatic cancer. Methods The clinical data of 103 T1-2N0M0 pancreatic cancer patients treated by CyberKnife SBRT at the Department of Radiation Oncology of Changhai Hospital from January 2012 to December 2016 was retrospectively analyzed. Kaplan-Meier method was used for survival analysis and Cox proportional hazards model was utilized to identify survival related factors. Results The median overall survival(OS) of T1-2N0M0 pancreatic cancer patients who had unresectable pancreatic cancer or refused surgery was 17.7(16.1-19.3) months. 1-year and 2-year OS rate were 86.3% and 24.6%, respectively. The median progression free survival(PFS) was 13.0(10.7-15.3) months. 1-year and 2-year PFS rate were 54.5% and 6.3%, respectively. Patients with chemoradiation, BED10≥60 Gy and CA19-9 decrease >50%after treatment had longer OS and PFS. Conclusions SBRT is a safe and effective treatment for patients with T1-2N0M0 pancreatic cancer. Key words: Pancreatic neoplasms; Radiotherapy; Treatment outcome

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.